Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique

Ceylan, Yasin; Akpınar, Gürler; Döğer, Emek; Kasap, Murat; Güzel, Nil; Karaosmanoğlu, Kübra; Köpük, Şule Yıldırım; Yücesoy, İzzet

doi:10.1016/j.jogoh.2019.101652

Cited by 10 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the past 20 years, the incidence of endometrial cancer has shown an obvious upward trend [31]. It is generally believed that endometrial lesions are a process in which the lesions continue to progress, that is, from not accompanied by EH to accompanied by EH, and finally progressing to well-differentiated EC [32,33]. However, some scholars [21,34] have reported that the incidence of EC in patients with endometrial hyperplasia is 12.18-46.34%.…”

Section: Discussionmentioning

confidence: 99%

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Zhao¹,

Hu²,

Zhao

et al. 2021

BMC Women's Health

View full text Add to dashboard Cite

Background Endometrial hyperplasia (EH) is commonly-seen in the patients with endometrial cancer (EC), we aimed to evaluated the risk factors of EC in patients with EH, to provide evidence to the clinical prevention and treatment of EC. Methods This study was a retrospective study design. EH patients confirmed by pathological examinations and treated with hysterectomy in our hospital from June 1, 2018 to February 28, 2021 were included. The clinical characteristics of EC and no-EC patients were compared and analyzed. Logistics regression analyses were conducted to evaluate the risk factors of EC in patients with EH. Results A total of 228 EH patients were included, the incidence of EC in the EH patients was 31.58%. There were significant differences in the age, BMI, diabetes, hypertension and pathology of EH between EC and no EC groups (all P < 0.05), no significant differences in the hyperlipidemia, preoperative CA125, number of deliveries, menopause and endometrial thickness between EC and no EC groups were found (all P > 0.05). Logistic regression analyses indicated that age > 50 y (OR 3.064, 95% CI 1.945–5.931), BMI ≥ 25 kg/m2 (OR 2.705, 95% CI 1.121–3.889), diabetes (OR 3.049, 95% CI 1.781–5.114), hypertension (OR 2.725, 95% CI 1.108–3.431) and severe hyperplasia (OR 3.181, 95% CI 1.496–4.228) were the risk factors of EC in patients with EH (all P < 0.05). Conclusions The risk of EC in EH patients is high, especially for those patients with age > 50 y, BMI ≥ 25 kg/m2, diabetes, hypertension and severe hyperplasia, special attentions should be paid for occurrence of EC and early diagnosis and early treatment are needed for those patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Zhao¹,

Hu²,

Zhao

et al. 2021

BMC Women's Health

View full text Add to dashboard Cite

show abstract

“…Only three studies have examined this aspect by considering the pre-cancer state (hyperplasia) in their research objective [10,17,18]. Byrjalsen et al [18] performed a proteomic analysis of patients with hyperplasia and carcinoma, and reported the differential expression of cellular transport and chaperoning proteins: heat shock protein 27 kDa protein, heat shock 70 kDa protein, heat shock cognate 71 kDa protein, and serotransferrin.…”

Section: Introductionmentioning

confidence: 99%

“…Seven proteins (haptoglobin, SERPINC 1, alpha-1-antichymotrypsin, apolipoprotein A-IV, interalpha-trypsin inhibitor heavy chain H4, and histidine-rich glycoprotein) were differentially expressed in atypical endometrial hyperplasia. Recently, Ceylan et al [17] compared the protein expression of complex atypical endometrial hyperplasia, endometrial carcinoma, and healthy endometrial tissues (D & C material) using two-dimensional difference gel electrophoresis (2D-DIGE). K2C8, UAP56, ENOA, ACTB, GRP78, GSTP1, PSME1, CALR, PPIA, PDIA3, and IDHc proteins were significantly expressed when comparing healthy participants and patients with cancer and complex atypical hyperplasia.…”

Section: Introductionmentioning

confidence: 99%

“…Although this study used the 2D-DIGE technique, pooled samples from different groups were used, which limited the statistical power of the study. Although these studies [10,17,18] employed proteomics as a tool, they could not clearly identify the differences between EC and hyperplasia. To the best of our knowledge, this study is the first to employ an untargeted proteomic approach to study the proteomic profiles of EC, hyper-plasia (HY), and control (Ctrl) groups using tissue samples from Saudi women.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tissue-Based Proteomic Profiling in Patients with Hyperplasia and Endometrial Cancer

Akkour

Alanazi

Alfadda

et al. 2022

Cells

View full text Add to dashboard Cite

Uterine cancers are among the most prevalent gynecological malignancies, and endometrial cancer (EC) is the most common in this group. This study used tissue-based proteomic profiling analysis in patients with endometrial cancer and hyperplasia, and control patients. Conventional 2D gel electrophoresis, followed by a mass spectrometry approach with bioinformatics, including a network pathway analysis pipeline, was used to identify differentially expressed proteins and associated metabolic pathways between the study groups. Thirty-six patients (twelve with endometrial cancer, twelve with hyperplasia, and twelve controls) were enrolled in this study. The mean age of the participants was 46–75 years. Eighty-seven proteins were significantly differentially expressed between the study groups, of which fifty-three were significantly differentially regulated (twenty-eight upregulated and twenty-five downregulated) in the tissue samples of EC patients compared to the control (Ctrl). Furthermore, 26 proteins were significantly dysregulated (8 upregulated and 18 downregulated) in tissue samples of hyperplasia (HY) patients compared to Ctrl. Thirty-two proteins (nineteen upregulated and thirteen downregulated) including desmin, peptidyl prolyl cis-trans isomerase A, and zinc finger protein 844 were downregulated in the EC group compared to the HY group. Additionally, fructose bisphosphate aldolase A, alpha enolase, and keratin type 1 cytoskeletal 10 were upregulated in the EC group compared to those in the HY group. The proteins identified in this study were known to regulate cellular processes (36%), followed by biological regulation (16%). Ingenuity pathway analysis found that proteins that are differentially expressed between EC and HY are linked to AKT, ACTA2, and other signaling pathways. The panels of protein markers identified in this study could be used as potential biomarkers for distinguishing between EC and HY and early diagnosis and progression of EC from hyperplasia and normal patients.

show abstract

“…Primary liver cancer commonly causes several deaths annually worldwide, [ 1 ] and hepatocellular carcinoma (HCC) is a major form of liver cancer. [ 2 ] Many factors contribute to HCC, including viral hepatitis, chemical carcinogens, polluted drinking water, tobacco and alcohol consumption, and genetic factors [ 3 ] ; however, the specific pathogenesis is unclear. Patients with HCC have a poor prognosis because of the complex pathogenesis and high recurrence rate, and most patients have complications such as liver cirrhosis.…”

Section: Introductionmentioning

confidence: 99%

Identification and validation of immune and prognosis-related genes in hepatocellular carcinoma: A review

et al. 2022

View full text Add to dashboard Cite

Bioinformatics methods were used to identify the key genes associated with the immune microenvironment of hepatocellular carcinoma (HCC) to construct an immune risk prognostic model (IRPM) and to study the correlation between IRPM's risk groups and immune characteristics of patients with HCC.Methods: HCC transcriptome sequencing information was searched for immune-related genes (IRGs) that were regularly expressed in cancer tissues. The IRGs, which were strongly linked to overall survival were screened; the prognostic characteristics model was constructed using Cox regression analysis. IRPM's independent prognostic value was explored; Kaplan-Meier survival and receiver-operating characteristic curves were used to determine the model prediction ability in the led-to queue.Results: Patients in the high-risk group (HRG) showed significantly poor outcomes. Gene Set Enrichment Analysis revealed factors involved in both the HRG and low risk group. Immune-related hub genes (IRHGs) and drug sensitivity expression levels revealed that all IRHGs were correlated with drug sensitivity for certain chemotherapy drugs. Conclusion:The study results may serve as a reference for improving prognosis, early screening, and immunotherapy in patients with HCC.Abbreviations: DEG = differentially expressed gene, GO = gene ontology, HCC = hepatocellular carcinoma, HRG = high-risk group, ICGC = International cancer genome consortium, IRG = immune-related gene, IRHG = immune-related hub gene, IRPM = immune risk prognostic model, KEGG = Kyoto encyclopedia of genes and genomes, K-M = Kaplan-Meier survival, LRG = low-risk group, OS = overall survival, PCA = principal component analysis, ROC = receiver-operating characteristic, TCGA = the cancer genome atlas, WGCNA = weighted gene co-expression network analysis.

show abstract

Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique

Cited by 10 publications

References 23 publications

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Tissue-Based Proteomic Profiling in Patients with Hyperplasia and Endometrial Cancer

Identification and validation of immune and prognosis-related genes in hepatocellular carcinoma: A review

Contact Info

Product

Resources

About